ExelixisEXEL
Recorded

Exelixis 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration27 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael SchmidtAnalyst

on with Exelixis. With me today, I have Andrew Peters, Chief Strategy Officer. My name is Michael Schmidt, Biotech Analyst with Guggenheim, and I am looking really forward to this. Welcome, Andrew. Good to see you.

Andrew PetersChief Strategy Officer

Thank you for having me.

Michael SchmidtAnalyst

Andrew, Exelixis just reported a solid third quarter earnings. The stock is near an all-time high. zanza is under FDA review. How would you describe Exelixis' focus today as you bridge from CABO to the zanza franchise?

Andrew PetersChief Strategy Officer

Yeah, it is a great place to start, actually. Thanks for the invite for the conference. Always great to be in Boston this time of year, and great meetings today. Before I begin, as a reminder, going to be making some forward-looking statements today, so please see relevant disclosures around the risks to our business in our filings with the SEC. The bridge to zanza is a great place to start with Exelixis right now. We are really at a fun time for the company, meaningful time for the company as we transition from this period of CABO being the TKI of choice in the 2020s towards our vision of zanza being the TKI of choice in the 2030s.

Andrew PetersChief Strategy Officer

Behind that, obviously, we have seven pivotal studies ongoing or that have read out with zanza in kind of that first wave, and then we've talked about wave two coming. From our perspective, we couldn't be more excited about everything that we have ongoing, kind of this emerging second franchise with zanza, while the CABO business continues to do extremely well, we're keeping our head down and just executing. That's really the theme of the company right now, is just executing across all of those pillars. First with CABO, then with zanza, and then it's that third and that fourth and that fifth asset, whether it's internal from our earlier stage portfolio or looking external from a BD perspective. That's kind of how we see the future as we transition from this blockbuster franchise CABO company to what's next.

Michael SchmidtAnalyst

Okay. Before we talk about zanza, I did want to spend a couple minutes on CABO, which is still growing, actually, 13% volume, I believe, in the third quarter. What has been the main growth driver at this stage in the life cycle of the product?

Andrew PetersChief Strategy Officer

Yeah. I mean, I think it's something that we're especially proud of. You highlighted the growth that we're continuing to see, and it's incredibly rare in this business to see that continued market share gain this long after a launch. As PJ talked about on the last earnings call, it's continuing to go out and work hard to fight for every market share point in RCC. Then in NETs, we're still in that first year or a little bit past our first year in the launch phase. That's just something that we're going to continue to fight and execute on as well.

Andrew PetersChief Strategy Officer

We've talked about new patient share and going out increasingly to the community and talking about the data, how it can be meaningful for patients, and just some of those dynamics that we've highlighted in the past around how NET patients are treated right now. But it's really that commercial execution and hyper-focus that we have, the commercial ops and analytics that we can go out and target prescribers, pockets of prescribers who maybe don't use CABO as much. Those are the sorts of things that we can do on the margin that are really paying dividends.

Michael SchmidtAnalyst

Okay. Is it fair to assume that NETs is now the main growth driver, or is RCC still contributing?

Andrew PetersChief Strategy Officer

As PJ talked about, we are seeing kind of growth across the board. Obviously, CABO is the number one TKI in RCC, and we are seeing very strong share in NETs as well. That is something that, again, our goal is to go out every day in the commercial organization and fight for every market share point, and we want to continue to do that.

Michael SchmidtAnalyst

Okay. As we think about sort of modeling CABO out through the end of its life cycle, you have obviously settled with most of the ANDA filers at this point, so I think there is less ambiguity around generic entry. There are a couple 505(b)(two) applications underway as well that are being pursued, an alternative strategy. One of them was approved recently. How do you think that might impact the CABO franchise?

Andrew PetersChief Strategy Officer

I think they are really kind of, I do not even want to say apples and oranges. It is apples and something pretty different there, between kind of the normal and the generics and the 505(b)(two) products. As a generalizable statement, 505(b)(two) products in oncology haven't really been successful commercially absent meaningful clinical data. You point to, I think ABRAXANE is probably the most famous example of a 505(b)(two) product. Their use and utilization is really driven by robust data that they were able to generate. Absent of that, given the non-AB rating, the non-substitutable, lack of guideline inclusion generally, those are all things that historically have really prevented these products from being adopted broadly. Our focus, again, is always on two things, maximizing and doing what is best for the patient. Two, ensuring our kind of intellectual property rights.

Andrew PetersChief Strategy Officer

Thematically, those are things that we're going to continue to do, and we're going to, as I said before, continue to fight for share in RCC.

Michael SchmidtAnalyst

Okay. Great. Then maybe a few questions on zanza. The STELLAR-303, the first phase III study, obviously met overall survival outcomes in colorectal cancer study in a full population. The FDA did extend the review a bit to March 3, PDUFA date, now next year. Just remind us what drove the push in timing, and how confident are you in approval at this point?

Andrew PetersChief Strategy Officer

Yeah. We're really excited about 303 and kind of the potential for the first approval of zanza there in kind of that CRC population. It's an indication where there continues to be a high unmet need. A lot of the market research that we're seeing right now is really favorable towards zanza there, kind of that chemo-free option, the checkpoint-containing option, the activity across all of those different patient subgroups, prior Bev and liver met, non-liver met, that kind of consistency of effect. So, we're seeing that excitement kind of building in the clinical community. As it relates to kind of the FDA, for obvious reasons, we don't really talk about ongoing interactions, but kind of at a very high level, they had asked for some data, we gave them data, and they said it's going to take a little more time to review the data.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day